Mark Cuban on Drug Price Transparency, PBM Contracts, and Healthcare Affordability

Mark Cuban discusses healthcare affordability and drug pricing transparency with Reuters, focusing on Cost Plus Drugs' cost-plus model, PBM and insurer contracting practices, and policy changes that could affect self-insured employers and patients. The conversation also addresses single-payer transition questions, domestic drug manufacturing, and AI-related risks and defenses in healthcare and cybersecurity.

■ Drug pricing transparency
- Cost Plus Drugs pricing model, API access, and use as a benchmark
- Consumer price comparison and insured/underinsured customer patterns

■ PBM, ASO, and employer contracting
- Contract complexity, spread pricing, rebates, and specialty drug definitions
- Self-insured employer direct contracting and published provider contracts via Cost Plus Wellness

■ Policy and single-payer
- Challenges in transitioning to a single-payer system
- Proposals on public contract disclosure, cash-pay purchases and deductibles, and nonprofit provider transparency

■ Manufacturing and AI
- Domestic manufacturing pods and ANDA economics for generics and N-of-1 therapies
- AI security concerns and defensive uses

Viewers interested in US healthcare economics, drug pricing, employer benefits strategy, and health policy will gain an overview of the issues and proposed transparency measures discussed. The session provides context for evaluating PBM contracts and policy debates rather than a step-by-step implementation guide.